TNFα inhibitors in the treatment of uveitis;TNFα-inhibitoren in der uveitistherapie

Ophthalmologe

Volumn 102, Issue 4, 2005, Pages 335-340

  Greiner, K ^a   Plskova, J ^b  

^a CARL THIEM KLINIKUM   (Germany)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

Beh et's disease; Clinical trials; Cytokines; TNF ; Uveitis

Indexed keywords

ADALIMUMAB; CORTICOSTEROID; CYCLOSPORIN A; CYTOKINE RECEPTOR ANTAGONIST; ETANERCEPT; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; ISONIAZID; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG; ANTIINFLAMMATORY AGENT;

DRUG EFFICACY; DRUG SAFETY; HUMAN; IMMUNE SYSTEM; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; REVIEW; RHEUMATOID ARTHRITIS; TREATMENT INDICATION; TUBERCULOSIS; UVEITIS; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG ANTAGONISM; DRUG COMBINATION; IMMUNOLOGY; PHYSIOLOGY; TREATMENT OUTCOME;

ADRENAL CORTEX HORMONES; ANTI-INFLAMMATORY AGENTS; CLINICAL TRIALS; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; UVEITIS;

EID: 17744387550     PISSN: 0941293X     EISSN: 14330423     Source Type: Journal    
DOI: 10.1007/s00347-004-1165-3     Document Type: Review

References (30)

1. Ahmad T, Wallace GR, James T et al. (2003) Mapping the HLA association in Behçet's disease: a role for tumor necrosis factor polymorphisms? Arthritis Rheum 48:807-813
2. Biester S, Michels H, Haefner R, Deuter CM, Schlote T, Kuemmerle-Deschner J, Zierhut M (2004) Etanercept in the treatment of chronic anterior uveitis in children (abstract). Association for Research and Vision in Ophthalmology 2004 Annual Meeting, Program #2668
3. Chen G, Goeddel DV (2002) TNF-R1 signaling: a beautiful pathway. Science 296:1634-1635
4. Derevjanik NL, Vinores SA, Xiao WH et al. (2002) Quantitative assessment of the integrity of the blood-retinal barrier in mice. Invest Ophthalmol Vis Sci 43:2462-2467
5. De Smet MD (2004) Remicade european study for chronic uveitis (abstract). European Association for Vision and Eye Research 2004 Annual Meeting, Program #1311
6. De Smet MD, Chan CC (2001) Regulation of ocular inflammation - what experimental and human studies have taught us. Prog Retin Eye Res 20:761-797
7. Dick AD, Duncan L, Hale G, Waldmann H, Isaacs J (1998) Neutralizing TNF-alpha activity modulates T-cell phenotype and function in experimental autoimmune uveoretinitis. J Autoimmun 11:255-264
8. El-Shabrawi Y, Hermann J (2002) Anti-tumor necrosis factor-alpha therapy with infliximab as an alternative to corticosteroids in the treatment of human leukocyte antigen B27-associated acute anterior uveitis. Ophthalmology 109:2342-2346
9. Fleischmann R, Yocum D (2004) Does safety make a difference in selecting the right TNF antagonist? Arthritis Res Ther 6 [Suppl 2]:S12-18
10. Foster CS, Tufail F, Waheed NK, Chu D, Miserocchi E, Baltatzis S, Vredeveld CM (2003) Efficacy of etanercept in preventing relapse of uveitis controlled by methotrexate. Arch Ophthalmol 121:437-440
11. Frost NA, Sparrow JM, Durant JS, Donovan JL, Peters TJ, Brookes ST (1998) Development of a questionnaire for measurement of vision-related quality of life. Ophthalmic Epidemiol 5:185-210
12. Jarrett SJ, Cunnane G, Conaghan PG, Bingham SJ, Buch MH, Quinn MA, Emery P (2003) Antitumor necrosis factor-alpha therapy-induced vasculitis: case series. J Rheumatol 30:2287-2291
13. Kaipiainen-Seppanen O, Leino M (2003) Recurrent uveitis in a patient with juvenile spondyloarthropathy associated with tumour necrosis factor alpha inhibitors. Ann Rheum Dis 62:88-89
14. Khanna D, McMahon M, Furst DE (2004) Safety of tumour necrosis factor-alpha antagonists. Drug Saf 27:307-324
15. Kwon HJ, Cote TR, Cuffe MS, Kramer JM, Braun MM (2003) Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann Intern Med 138:807-811
16. Louis M, Rauch J, Armstrong M, Fitzcharles MA (2003) Induction of autoantibodies during prolonged treatment with infliximab. J Rheumatol 30:2557-2562
17. Murphy CC, Greiner K, Plskova J et al. (2004) Neutralizing tumor necrosis factor activity leads to remission in patients with refractory noninfectious posterior uveitis. Arch Ophthalmol 122:845-851
18. Ohno S, Nakamura S, Hori S et al. (2004) Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behçet's disease with refractory uveoretinitis. J Rheumatol 31:1362-1368
19. O'Shea JJ, Ma A, Lipsky P (2002) Cytokines and autoimmunity. Nat Rev Immunol 2:37-45
20. Reddy AR, Backhouse OC (2003) Does etanercept induce uveitis? Br J Ophthalmol 87:925
21. Reiff A (2003) Long-term outcome of etanercept therapy in children with treatment-refractory uveitis. Arthritis Rheum 48:2079-2080
22. Santos Lacomba M, Marcos Martin C, Gallardo Galera JM, Gomez Vidal MA, Collantes Estevez E, Ramirez Chamond R, Omar M (2001) Aqueous humor and serum tumor necrosis factor-alpha in clinical uveitis. Ophthalmic Res 33:251-255
23. Sfikakis PR, Kaklamanis PH, Elezoglou A, Katsilambros N, Theodossiadis PG, Papaefthimiou S, Markomichelakis N (2004) Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades-Behçet disease. Ann Intern Med 140:404-406
24. Smith JR, Hart PH, Coster DJ, Williams KA (1998) Mice deficient in tumor necrosis factor receptors p55 and p75, interleukin-4, or inducible nitric oxide synthase are susceptible to endotoxin-induced uveitis. Invest Ophthalmol Vis Sci 39:658-661
25. Smith JR, Levinson RD, Holland GN, Jabs DA, Robinson MR, Whitcup SM, Rosenbaum JT (2001) Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease. Arthritis Rheum 45:252-257
26. Suhler EB, Smith JR, Lauer AK, Kurz DE, Wertheim MS, Pickard TD, Rosenbaum JT (2004) A prospective trial of Infliximab therapy for patients with refractory uveitis: interim analysis of safety and efficacy outcomes (abstract). Association for Research and Vision in Ophthalmology 2004 Annual Meeting, Program #3370
27. The Lenercept Multiple Sclerosis Study Group (1999)TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. Neurology 53:457-465
28. Tugal-Tutkun I, Gul A, Mudun A, Inane M, Kamali S, Urgancioglu M (2004) Efficacy of Infliximab in the treatment of uveitis resistant to the combination of Azathioprine and Cyclosporin in Behçet's disease (abstract). Association for Research and Vision in Ophthalmology 2004 Annual Meeting, Program #2670
29. U.S. Food and Drug Administration, Rockville, MD (2004)http://www.fda.gov
30. Wolfe F, Michaud K, Anderson J, Urbansky K (2004) Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum 50:372-379